<DOC>
	<DOCNO>NCT00155766</DOCNO>
	<brief_summary>Chemotherapy current standard treatment unresectable recurrent cervical carcinoma radiotherapy distant metastasis cervical carcinoma . The effective regimen cisplatin-based chemotherapy . After failure cisplatin-based chemotherapy , still treatment prove effective . Human papilloma virus ( HPV ) consistently implicate cause cervical cancer especially high-risk type ( HPV 16,18,31,45 ) strongly associate cervical cancer . HPV 16 find 50 % cervical cancer tissue . Results many animal tumor model indicate immunization tumor antigen-pulsed dendritic cell trigger long-lasting anti-tumor immune response significantly inhibit growth implanted tumor cell . Recently , many clinical trial conduct evaluate feasibility safety immunize cancer patient tumor antigen-pulsed dendritic cell . No severe toxicity report patient show respond treatment . Based previous animal clinical study investigator , propose evaluate potential immunizing cancer patient antigen-pulsed autologous dendritic cell cancer vaccine treat recurrent cervical cancer failure cisplatin-based chemotherapy treatment refuse chemotherapy . In study , generate dendritic cell culture patient 's autologous PBMC GM-CSF IL-4 vitro . These dendritic cell pulse synthetic peptide represent CTL epitope HPV Type 16 E7 . Antigen-pulsed dendritic cell inject inguinal lymph node guidance real-time sonography . Each patient receive four injection 12 patient total recruit study .</brief_summary>
	<brief_title>Immunotherapy Recurrent Cervical Cancers Using Dendritic Cells ( DCs )</brief_title>
	<detailed_description>Chemotherapy current standard treatment unresectable recurrent cervical carcinoma radiotherapy distant metastasis cervical carcinoma . The effective regimen cisplatin-based chemotherapy . After failure cisplatin-based chemotherapy , still treatment prove effective . Human papilloma virus ( HPV ) consistently implicate cause cervical cancer especially high-risk type ( HPV 16,18,31,45 ) strongly associate cervical cancer . HPV 16 find 50 % cervical cancer tissue . Results many animal tumor model indicate immunization tumor antigen-pulsed dendritic cell trigger long-lasting anti-tumor immune response significantly inhibit growth implanted tumor cell . Recently , many clinical trial conduct evaluate feasibility safety immunize cancer patient tumor antigen-pulsed dendritic cell . No severe toxicity report patient show respond treatment . Based previous animal clinical study investigator , propose evaluate potential immunizing cancer patient antigen-pulsed autologous dendritic cell cancer vaccine treat recurrent cervical cancer failure cisplatin-based chemotherapy treatment refuse chemotherapy . In study , generate dendritic cell culture patient 's autologous PBMC GM-CSF IL-4 vitro . These dendritic cell pulse synthetic peptide represent CTL epitope HPV Type 16 E7 . Antigen-pulsed dendritic cell inject inguinal lymph node guidance real-time sonography . Each patient receive four injection 12 patient total recruit study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>1. recurrent cervical cancer 2 . HPV 16 infection 3 . Previously receive cisplatin ot 5FU base chemotherapy refuse receive chemotherapy 4 . HLAA2 haplotype 5 . Older 20 year old 6 . ECOG I II 7 . Life expectancy longer 3 month 8 . Adequate bone marrow reserve 9. pregnancy test : negative 10 . Informed consent obtain 1 . CNS metastasis 2 . Acute chronic infection 3 . Pregnant lactate woman 4 . Asthma 5 . Cardiac disease heart failure , unstable angina , arrhythmia , myocardial infarction 6 . Autoimmune disease 7 . Previously cancer ( except basal cell cancer ) 8 . Without chemotherapy , biotherapy 6 week</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>cervical cancer , immunotherapy , DC</keyword>
</DOC>